Clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases.
Prothena Corporation plc, a prominent late-stage clinical company based in Dublin, Ireland, specializes in the discovery and development of innovative therapies aimed at tackling life-threatening diseases, primarily within the United States. Central to its portfolio is Birtamimab, an investigational humanized antibody currently undergoing Phase III clinical trials for the treatment of AL amyloidosis. Additionally, the company is advancing Prasinezumab, a humanized monoclonal antibody in Phase IIb trials targeting Parkinson's disease, and PRX004, which has completed Phase I trials for Transthyretin amyloidosis. Further expanding its therapeutic pipeline, Prothena is also investigating PRX005 in Phase I trials for Alzheimer's disease.
Founded in 2012, Prothena Corporation plc benefits from a robust research and development framework, bolstered by strategic partnerships. The company collaborates closely with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., under a comprehensive agreement to develop and commercialize antibodies targeting alpha-synuclein, a critical protein implicated in neurodegenerative diseases. Additionally, a collaboration with Bristol-Myers Squibb focuses on advancing novel antibody therapies, reflecting Prothena's commitment to fostering cutting-edge treatments through collaborative efforts.
Prothena's dedication extends beyond clinical programs to encompass robust discovery and presclinical initiatives. Among its promising developments are PRX012, aimed at addressing Alzheimer's disease, and a dual Aß-Tau vaccine designed for both treatment and prevention of this challenging neurodegenerative condition. With a focus on scientific excellence and patient-centric innovation, Prothena Corporation plc continues to push boundaries in biopharmaceutical research, striving to deliver transformative therapies that offer new hope for patients worldwide.
Operating from Dublin, Ireland, Prothena Corporation plc strategically positions itself within a global hub of biomedical innovation. The company's headquarters serve as a pivotal center for its international operations, facilitating collaborations with leading experts and institutions in the field. Prothena remains steadfast in its mission to advance the frontier of therapeutic possibilities, aiming to redefine standards of care and improve outcomes for individuals confronting severe and debilitating diseases.